BRCA1 and cancer: An attractive hypothesis to be tested in clinical studies will be whether also methylation of BRCA1 in a significant fraction of sporadic breast and ovarian cancers, and possibly of FANC-F in breast tumours, can determine the response of such cancers to treatment with cross-linking drugs.